According to our estimates, just under 50 companies accounted for more than 85% of all orthopedic revenue in 2023.

Orthopedics’ Top Tier to Expand in 2024

According to our estimates, just under 50 companies accounted for more than 85% of all orthopedic revenue in 2023.

The Numbers
Stay up to date on the orthopedic market's 4Q performance in 2023 as we update this post with company sales data and industry developments.

Orthopedic Volume Trends Remained Strong in Fourth Quarter

Stay up to date on the orthopedic market’s 4Q performance in 2023 as we update this post with company sales data and industry developments.

Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.

10 Orthopedic Companies Close New Funding Rounds in 1Q24

Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.

Orthoflash®
16 Bit offers Rho, AI-enabled software aimed at improving a known care gap in osteoporosis screening.
FDA De Novo for 16 Bit Bone Density Screening Tool

16 Bit offers Rho, AI-enabled software aimed at improving a known care gap in osteoporosis screening.

,
Lipogems ARISE I U.S. FDA IDE study
Enrollment Complete in Lipogems ARISE I Study

Lipogems completed enrollment in the ARISE I FDA IDE study examining MicroFat vs. corticosteriod injection for the treatment of knee OA.

,
Onkos Surgical ELEOS Proximal Tibia
FDA De Novo for Onkos Surgical’s Antibacterial Coating

Preclinical data demonstrate that the proprietary coating does not elute and has been proven to be bactericidal.

,
The first patient is enrolled in ARISE II, an IDE research study to examine investigational MicroFat vs. saline injection to treat knee OA.
Lipogems Enrolls 2nd Trial for Knee Osteoarthritis

The first patient is enrolled in ARISE II, an IDE research study to examine investigational MicroFat vs. saline injection to treat knee OA.

,
Ensemble Orthopedics CMC Joint Replacement
Ensemble Orthopedics’ 700th Implantation of Pyrocarbon Interpositional CMC

The Ensemble CMC joint replacement was developed as a minimally invasive treatment of thumb osteoarthritis.

,
Competitive Landscape
Industry Voices

Contact Us

0